Skip to Content

Oncology Clinical Trials Decline During Pandemic

WEDNESDAY, Feb. 3, 2021 -- The COVID-19 pandemic was associated with a 60 percent decrease in the number of launches of oncology clinical trials of drugs and biologic therapies, according to a research letter published online Jan. 27 in JAMA Network Open.

Elizabeth B. Lamont, M.D., from Acorn AI in Boston, and colleagues evaluated the association between the pandemic and clinical cancer research and development by studying the initiation of oncology clinical trials over time. The analysis used operational clinical trial data from the Medidata Enterprise Data Store to aggregate all phase 1 through 4 oncology trials of drugs or biological agents that opened for patient accrual (launched) during the eight consecutive months of October through May over five successive years, with January through May 2020 defined as the pandemic period.

The researchers identified 1,440 oncology-directed trials of drugs or biological agents that launched in 91 countries. In each of the five sequential eight-month launch periods, the distribution of trials was: 229, 304, 340, 376, and 191 trials, respectively. There was a 60 percent decrease in oncology trial launches during the pandemic period (incidence rate ratio, 0.40) versus the prepandemic period, with constant trial launches in each of the five observation periods.

"The COVID-19 pandemic may be associated with longer term indirect effects on population morbidity and mortality through pathways such as arrested drug development," the authors write.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Read this next

Response to One Dose of COVID-19 Vaccine Strong for Previously Infected

TUESDAY, March 2, 2021 -- Individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection generate strong responses to one dose of the BNT162b2...

Only Two in 10 Older Adults Report Being Screened for Hearing Loss

TUESDAY, March 2, 2021 -- Eight in 10 older adults say they have not been screened for hearing loss in primary care within the last two years, according to a report published...

​IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19​

TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.